PITAVASTATIN

CLL

University of California, IrvineSmall moleculePhase 1Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 89/ 100

Competitive context

10 Active assets in the CLL cohort.

Asset / Sponsor	Phase	Rating
Ppsv23 Region Örebro County	Phase 4	BB
Conjugated Pneumococcal Vaccine Region Örebro County	Phase 4	BB
Benadryl National Cancer Institute (NCI)	Phase 2	B
sb-497115-gr University of Ulm	Phase 2	B
Gm-Csf Beth Israel Deaconess Medical Center	Phase 2	B

View all 22 →

Same molecule, other indications

PITAVASTATIN is also rated in:

HypercholesterolemiaDormant

BBB

Indicative ·

74 / 100

coronary artery disorderDormant

BBB

Indicative ·

73 / 100

abdominal obesity-metabolic syndromeDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.